It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Spiradenoma and cylindroma are distinctive skin adnexal tumors with sweat gland differentiation and potential for malignant transformation and aggressive behaviour. We present the genomic analysis of 75 samples from 57 representative patients including 15 cylindromas, 17 spiradenomas, 2 cylindroma–spiradenoma hybrid tumors, and 24 low- and high-grade spiradenocarcinoma cases, together with morphologically benign precursor regions of these cancers. We reveal somatic or germline alterations of the CYLD gene in 15/15 cylindromas and 5/17 spiradenomas, yet only 2/24 spiradenocarcinomas. Notably, we find a recurrent missense mutation in the kinase domain of the ALPK1 gene in spiradenomas and spiradenocarcinomas, which is mutually exclusive from mutation of CYLD and can activate the NF-κB pathway in reporter assays. In addition, we show that high-grade spiradenocarcinomas carry loss-of-function TP53 mutations, while cylindromas may have disruptive mutations in DNMT3A. Thus, we reveal the genomic landscape of adnexal tumors and therapeutic targets.
Spiradenoma and cylindroma are skin adnexal tumors that can behave aggressively and undergo malignant transformation. Here, the authors genetically assess a cohort of these adnexal tumours, highlighting recurrent ALPK1 mutations and revealing the genomic landscape of these rare tumours.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 Wellcome Trust Sanger Institute, Experimental Cancer Genetics, Cambridge, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382)
2 Maasstad Hospital, Department of Pathology, Rotterdam, The Netherlands (GRID:grid.416213.3) (ISNI:0000 0004 0460 0556)
3 Dermatopathologie Friedrichshafen, Friedrichshafen, Germany (GRID:grid.500037.1)
4 Division of Cancer Biology. Institute of Cancer Research, Dynamical Cell Systems Laboratory. Chester Beatty Laboratories, London, UK (GRID:grid.18886.3f) (ISNI:0000 0001 1271 4623)
5 Medical Faculty University of Ljubljana, Institute of Pathology, Ljubljana, Slovenia (GRID:grid.8954.0) (ISNI:0000 0001 0721 6013)
6 University Hospital Center Zagreb, Zagreb, Croatia (GRID:grid.412688.1) (ISNI:0000 0004 0397 9648)
7 Institut Jules Bordet, Brussels, Belgium (GRID:grid.418119.4) (ISNI:0000 0001 0684 291X)
8 Cleveland Clinic, Department of Pathology, Cleveland, USA (GRID:grid.239578.2) (ISNI:0000 0001 0675 4725)
9 University of Calgary, Departments of Pathology & Laboratory Medicine and Medicine and The Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697)
10 University of Michigan Medical School, Departments of Pathology and Dermatology, Ann Arbor, USA (GRID:grid.214458.e) (ISNI:0000000086837370)
11 The University of Edinburgh, Institute of Genetics & Molecular Medicine, Division of Pathology, Cancer Research UK Edinburgh Centre, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)
12 Wellcome Trust Sanger Institute, Experimental Cancer Genetics, Cambridge, UK (GRID:grid.10306.34) (ISNI:0000 0004 0606 5382); Universidad Nacional Autónoma de México, Laboratorio Internacional de Investigación sobre el Genoma Humano, Santiago de Querétaro, Mexico (GRID:grid.9486.3) (ISNI:0000 0001 2159 0001)
13 Harvard Medical School, Department of Pathology, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
14 University of Calgary, Departments of Pathology & Laboratory Medicine and Medicine and The Arnie Charbonneau Cancer Institute, Cumming School of Medicine, Calgary, Canada (GRID:grid.22072.35) (ISNI:0000 0004 1936 7697); The University of Edinburgh, Institute of Genetics & Molecular Medicine, Division of Pathology, Cancer Research UK Edinburgh Centre, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988)